Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Walgreens Boots Alliance Inc. Is Being Sued For Possible Securities Fraud And Affected Stakeholders Are Urged To Contact The Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

The Schall Law Firm Wants Walgreens Boots Alliance Inc Investors To Reach Out About A Case For Securities Related Impropriety

Altria

Verizon

Walgreens is resetting its business, including a decision to close a large number of stores. Altria is a large U.S. cigarette maker trying to find a new growth engine.

Should You Buy the 3 Highest-Yielding Dividend Stocks in the S&P 500?

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Shareholders In Walgreens Boots Alliance Inc. Are Reminded Of A Securities Fraud Lawsuit And Encouraged To Contact The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 30, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=99263&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Walgreens Boots Alliance, Inc. (WBA) - September 10, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK CITY, NY / ACCESSWIRE / August 30, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=99201&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 10, 2024 in Walgreens Boots Alliance, Inc. Lawsuit – WBA

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=99110&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Walgreens Boots Alliance, Inc. (WBA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Shareholders In Walgreens Boots Alliance Inc. Are Encouraged To Contact The Schall Law Firm About A Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=99076&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Walgreens Boots Alliance, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 - WBA

NEW YORK CITY, NY / ACCESSWIRE / August 29, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK , Aug. 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 10, 2024 in Walgreens Lawsuit - WBA

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Walgreens Boots Alliance, Inc. ("Walgreens" or the "Company") (NASDAQ: WBA) of a class action securities lawsuit.

Levi & Korsinsky Notifies Walgreens Boots Alliance, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – WBA

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Walgreens Boots Alliance Inc Is Being Sued For Securities Law Infractions And The Schall Law Firm Urges Investors To Reach Out

Walgreens Boots Alliance Inc. (NASDAQ: WBA) has endured a dramatic decline in its stock value, plummeting over 65% this year. The company's challenges are intensifying, with new competitive pressures from pharmaceutical giants Pfizer Inc. (NYSE: PFE) and Eli Lilly & Co. (NYSE: LLY).

Pfizer and Eli Lilly's new moves intensify Walgreens' struggles

NEW YORK CITY, NY / ACCESSWIRE / August 28, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Walgreens securities between October 12, 2023, and June 26, 2024, inclusive (the "Class Period").

WBA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Walgreens Boots Alliance, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=98702&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by September 10, 2024 Deadline to Join Class Action Against Walgreens Boots Alliance, Inc.(WBA)

CVS Health

One of the saddest finance stories is unfolding in the United States, where Walgreens Boots Alliance (WBA) is imploding and becoming a fallen angel. The stock has crashed by over 68% this year and by 80% in the past five years.

Walgreens stock has fallen apart: is CVS Health any better?

Walgreens stock shed 9% of its value yesterday - faring far worse than its peer CVS Health which lost 3%. This means that the stock is now trading at a level more than 60% below what it started the year at.

Bitter Pill To Swallow: Why Walgreens Stock Is Down 60% This Year

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=98571&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Walgreens Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 – WBA

Major drugmakers Pfizer and Eli Lilly made major direct-to-consumer announcements. While Walgreens was named as a partner for Pfizer's new direct health platform, it stands to potentially lose out on retail drug sales.

Why Walgreens Boots Alliance Plunged Today

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).

Walgreens Boots Alliance, Inc. Class Action: The Gross Law Firm Reminds Walgreens Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 – WBA

The leading resident loyalty and payments program, Bilt, is collaborating with Walgreens in the healthcare space.

Walgreens and Bilt want to help you stop wasting money on healthcare when FSA dollars expire

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

News for Walgreens Stock (WBA)